Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | GUCY1A1 | Q02108 | 8/20 | 0.52 |
| ▸ | GUCY1B1 | Q02153 | 8/20 | 0.52 |
| ▸ | PDE5A | O76074 | 10/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459383 | 0.93 | KCNH2 (0.81) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL174905 | 0.92 | KCNH2 (0.79) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5765138 | 0.91 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL32675709 | 0.91 | ADORA3 (0.70) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL5480733 | 0.91 | ADORA3 (0.70) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL255819 | 0.91 | ADORA3 (0.78) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL175338 | 0.91 | ADORA3 (0.78) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL256202 | 0.90 | KCNH2 (0.84) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL245457 | 0.90 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29379983 | 0.90 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | ADORA3 814/4885KCNH2 1555/4885GUCY1A1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.